Associations between ICI efficacy and predictors of treatment response such as programmed cell death ligand 1 (PD-L1), tumor mutational burden (TMB), and microsatellite instability/defective mismatch repair (MSI/dMMR) have been reported [5–10]. This evidence concerns the gene CD274 and neoplasm.